Released on August 9, 2012
After a thorough review, the Saskatchewan Ministry of Health has approved coverage of a new drug for a three-year old Langenburg resident who has a rare enzyme deficiency condition called mucopolysaccharidosis VI (MPS VI). The request to cover Naglazyme was received by the Saskatchewan Drug Plan on July 9, 2012.
The coverage decision took into consideration the drug's clinical effectiveness, cost and safety implications.
Individuals with MPS VI lack an enzyme which leads to the accumulation of complex sugar molecules that can result in complications such as skeletal deformities, joint disease, eye disease and cardiopulmonary disease.
While there is no known cure for MPS VI, Naglazyme (galsulfase), an enzyme replacement therapy, is designed to provide patients with a synthetic version of the enzyme they are lacking by infusing small doses into the patient's bloodstream on a weekly basis. To date, there are nine confirmed cases of MPS VI in Canada.
Coverage of the medication is approved on a case-by-case basis, and will cost between $250,000 and $300,000 annually for this patient.
-30-
For more information, contact:
Tyler McMurchy
Health
Regina
Phone: 306-787-4083
Email: tmcmurchy@health.gov.sk.ca